Survivin in esophageal cancer: An accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma
Open Access
- 18 July 2006
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 119 (7) , 1717-1722
- https://doi.org/10.1002/ijc.21923
Abstract
We quantified the expression of survivin, both as mRNA in real-time PCR and protein in immunohistochemistry, in tumor samples of 112 patients with esophageal cancer (56 squamous cell carcinomas and 56 adenocarcinomas). Overall survival of squamous cell carcinoma patients with high survivin mRNA levels was significantly less than that of patients with low survivin mRNA levels (p = 0.0033). Distribution pattern of survivin (nuclear vs. cytoplasmic or mixed) was not correlated to survival, while the extent of immunostaining was significantly correlated to survivin mRNA values (p = 0.016) and had prognostic relevance in univariate analysis (p = 0.0012). Cox's proportional-hazard regression model showed that tumor survivin expression in esophageal squamous cell carcinoma was the most important prognostic factor, independent of tumor stage and other histopathological factors, both as mRNA relative value (p = 0.0259) and protein immunostaining (p = 0.0147). In esophageal adenocarcinoma, survivin expression and pattern of distribution had no prognostic relevance. Thus, quantifying survivin expression provides a prognostic marker only for esophageal squamous tumors.Keywords
This publication has 26 references indexed in Scilit:
- Epidemiologic risk factors for Barrett’s esophagus and associated adenocarcinomaClinical Gastroenterology and Hepatology, 2004
- Nuclear or cytoplasmic expression of survivin: What is the significance?International Journal of Cancer, 2004
- Prognostic significance and different properties of survivin splicing variants in gastric cancerCancer Letters, 2004
- Inhibitor of Apoptosis Proteins: Translating Basic Knowledge into Clinical PracticeCancer Research, 2004
- Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivinVaccine, 2004
- Focus on Barrett's esophagus and esophageal adenocarcinomaCancer Cell, 2004
- Biomarkers of Esophageal Adenocarcinoma and Barrett’s EsophagusCancer Research, 2004
- Apoptotic and Proliferative Indexes in Esophageal CancerJournal of Gastrointestinal Surgery, 2003
- Validating survivin as a cancer therapeutic targetNature Reviews Cancer, 2003
- Molecular and Clinical Differences between Adenocarcinomas of the Esophagus and of the Gastric CardiaThe American Journal of Pathology, 2001